EN9 Stock Overview
A life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Enzymatica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.14 |
| 52 Week High | SEK 0.34 |
| 52 Week Low | SEK 0.13 |
| Beta | -0.014 |
| 11 Month Change | 3.58% |
| 3 Month Change | -27.02% |
| 1 Year Change | -53.39% |
| 33 Year Change | -86.96% |
| 5 Year Change | n/a |
| Change since IPO | -91.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| EN9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.8% | -3.8% | 0.6% |
| 1Y | -53.4% | -15.5% | 11.8% |
Return vs Industry: EN9 underperformed the German Pharmaceuticals industry which returned -15.5% over the past year.
Return vs Market: EN9 underperformed the German Market which returned 11.8% over the past year.
Price Volatility
| EN9 volatility | |
|---|---|
| EN9 Average Weekly Movement | 21.8% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EN9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EN9's weekly volatility has increased from 14% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 16 | Claus Egstrand | www.enzymatica.se |
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care.
Enzymatica AB (publ) Fundamentals Summary
| EN9 fundamental statistics | |
|---|---|
| Market cap | €27.78m |
| Earnings (TTM) | -€4.93m |
| Revenue (TTM) | €3.96m |
7.0x
P/S Ratio-5.6x
P/E RatioIs EN9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EN9 income statement (TTM) | |
|---|---|
| Revenue | SEK 44.95m |
| Cost of Revenue | SEK 16.19m |
| Gross Profit | SEK 28.76m |
| Other Expenses | SEK 84.72m |
| Earnings | -SEK 55.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 63.99% |
| Net Profit Margin | -124.47% |
| Debt/Equity Ratio | 38.7% |
How did EN9 perform over the long term?
See historical performance and comparison